Patients with advanced Parkinson’s disease (PD) often need to continue with device-aided therapies (DAT), such as intestinal and subcutaneous infusion therapies. Recently, continuous subcutaneous administration of foslevodopa/foscarbidopa (LDp/CDp) has emerged as a new therapeutic method. Two years after its approval i...
D. Weise, Tobias Warnecke, Carsten Buhmann et al.· Neurological Research and Pr...· 0 citations
We are in an era in which increasing numbers of potentially disease-modifying treatments for Parkinson's disease are being tested in clinical development. Current definitions of disease modification have inherent limitations; hence there is a need to establish a clear, unified definition. This unified definition of dis...
A. Antonini, Robert E. Gross, María Lucia De León et al.· Journal of Parkinson's Disea...· 0 citations
A synthesis of recent neuroimaging evidence on resilience mechanisms in Parkinson's disease is provided to clarify the terminology, define the mechanisms and relate resilience mechanisms to treatments, including dopamine replacement therapy and deep brain stimulation.
M. C. Ruppert-Junck, T. van Eimeren, Kathrin Giehl et al.· Brain : a journal of neurolo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
